Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (31-40 of 292) with videos related to

Pageof 30
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|May 1, 2012
Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activationAnh N Nguyen, Justin T Hoffman, Shirley M Tsunoda, et al.
Drug Design, Development and Therapy|January 7, 2022
Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional EsomeprazoleSungyeun Bae, Jihoon Kwon, Si-Beum Lee, et al.
Drug Design, Development and Therapy|April 28, 2023
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy SubjectsHyun Chul Kim, Sangmi Lee, Siyoung Sung, et al.
Clinical and Translational Science|January 19, 2022
Single-dose of LC51-0255, a selective S1P<sub>1</sub> receptor modulator, showed dose-dependent and reversible reduction of absolute lymphocyte count in humansSang Won Lee, Inyoung Hwang, Jaeseong Oh, et al.
Frontiers in Pharmacology|September 8, 2022
Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjectsInyoung Hwang, Sang Won Lee, Jaeseong Oh, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 3, 2025
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteersFriedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Clinical Pharmacology in Drug Development|March 17, 2023
Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed-Release Formulation of Esomeprazole in Healthy SubjectsSejung Hwang, Sung Hee Hong, Jina Jung, et al.
Drug Design, Development and Therapy|March 3, 2018
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjectsYu Kyong Kim, Kwang-Hee Shin, Jeffrey Alderman, et al.
Translational and Clinical Pharmacology|July 8, 2022
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combinationHyun Chul Kim, Deok Yong Yoon, SeungHwan Lee, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 10, 2023
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapySoyoung Lee, Kyung Taek Hong, In-Jin Jang, et al.
Pageof 30

Showing results (31-40 of 292) with videos related to

Sort By:
Pageof 30
International Journal of Clinical Pharmacology and Therapeutics|May 1, 2012
Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activationAnh N Nguyen, Justin T Hoffman, Shirley M Tsunoda, et al.
Drug Design, Development and Therapy|January 7, 2022
Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional EsomeprazoleSungyeun Bae, Jihoon Kwon, Si-Beum Lee, et al.
Drug Design, Development and Therapy|April 28, 2023
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy SubjectsHyun Chul Kim, Sangmi Lee, Siyoung Sung, et al.
Clinical and Translational Science|January 19, 2022
Single-dose of LC51-0255, a selective S1P<sub>1</sub> receptor modulator, showed dose-dependent and reversible reduction of absolute lymphocyte count in humansSang Won Lee, Inyoung Hwang, Jaeseong Oh, et al.
Frontiers in Pharmacology|September 8, 2022
Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjectsInyoung Hwang, Sang Won Lee, Jaeseong Oh, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 3, 2025
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteersFriedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Clinical Pharmacology in Drug Development|March 17, 2023
Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed-Release Formulation of Esomeprazole in Healthy SubjectsSejung Hwang, Sung Hee Hong, Jina Jung, et al.
Drug Design, Development and Therapy|March 3, 2018
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjectsYu Kyong Kim, Kwang-Hee Shin, Jeffrey Alderman, et al.
Translational and Clinical Pharmacology|July 8, 2022
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combinationHyun Chul Kim, Deok Yong Yoon, SeungHwan Lee, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 10, 2023
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapySoyoung Lee, Kyung Taek Hong, In-Jin Jang, et al.
Pageof 30